These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 1365538)

  • 1. Cytomegalovirus vaccines: current status.
    Starr SE
    Infect Agents Dis; 1992 Jun; 1(3):146-8. PubMed ID: 1365538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients.
    Plotkin SA; Higgins R; Kurtz JB; Morris PJ; Campbell DA; Shope TC; Spector SA; Dankner WM
    Transplantation; 1994 Dec; 58(11):1176-8. PubMed ID: 7992358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress toward developing a cytomegalovirus vaccine.
    Marshall GS; Plotkin SA
    Infect Dis Clin North Am; 1990 Jun; 4(2):283-98. PubMed ID: 2161034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines.
    Heineman TC; Schleiss M; Bernstein DI; Spaete RR; Yan L; Duke G; Prichard M; Wang Z; Yan Q; Sharp MA; Klein N; Arvin AM; Kemble G
    J Infect Dis; 2006 May; 193(10):1350-60. PubMed ID: 16619181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).
    Adler SP; Plotkin SA; Gonczol E; Cadoz M; Meric C; Wang JB; Dellamonica P; Best AM; Zahradnik J; Pincus S; Berencsi K; Cox WI; Gyulai Z
    J Infect Dis; 1999 Sep; 180(3):843-6. PubMed ID: 10438376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The status of cytomegalovirus vaccine.
    Starr SE; Friedman HM; Plotkin SA
    Rev Infect Dis; 1991; 13 Suppl 11():S964-5. PubMed ID: 1664136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current prospects for immunization against cytomegaloviral disease.
    Adler SP
    Infect Agents Dis; 1996 Jan; 5(1):29-35. PubMed ID: 8789597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients.
    Jacobson MA; Sinclair E; Bredt B; Agrillo L; Black D; Epling CL; Carvidi A; Ho T; Bains R; Adler SP
    J Clin Virol; 2006 Mar; 35(3):332-7. PubMed ID: 16387547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The prevention of cytomegalovirus infection and disease by administration of biological products].
    Ihara T
    Nihon Rinsho; 1998 Jan; 56(1):145-50. PubMed ID: 9465680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress toward an elusive goal: current status of cytomegalovirus vaccines.
    Schleiss MR; Heineman TC
    Expert Rev Vaccines; 2005 Jun; 4(3):381-406. PubMed ID: 16026251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of cytomegalovirus disease by Towne strain live attenuated vaccine.
    Plotkin SA; Smiley ML; Friedman HM; Starr SE; Fleisher GR; Wlodaver C; Dafoe DC; Friedman AD; Grossman RA; Barker CF
    Birth Defects Orig Artic Ser; 1984; 20(1):271-87. PubMed ID: 6329367
    [No Abstract]   [Full Text] [Related]  

  • 12. Detection of cytomegalovirus infection during a vaccine clinical trial in healthy young women: seroconversion and viral shedding.
    Zhang C; Buchanan H; Andrews W; Evans A; Pass RF
    J Clin Virol; 2006 Mar; 35(3):338-42. PubMed ID: 16388984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant.
    Pass RF; Duliegè AM; Boppana S; Sekulovich R; Percell S; Britt W; Burke RL
    J Infect Dis; 1999 Oct; 180(4):970-5. PubMed ID: 10479120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoprophylaxis against cytomegalovirus disease.
    Adler SP
    Scand J Infect Dis Suppl; 1995; 99():105-9. PubMed ID: 8668931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus vaccine in renal transplant candidates: progress report of a randomized, placebo-controlled, double-blind trial.
    Balfour HH; Sachs GW; Welo P; Gehrz RC; Simmons RL; Najarian JS
    Birth Defects Orig Artic Ser; 1984; 20(1):289-304. PubMed ID: 6329368
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12.
    Jacobson MA; Sinclair E; Bredt B; Agrillo L; Black D; Epling CL; Carvidi A; Ho T; Bains R; Girling V; Adler SP
    Vaccine; 2006 Jun; 24(25):5311-9. PubMed ID: 16701925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a cytomegalovirus vaccine: lessons from recent clinical trials.
    Gonczol E; Plotkin S
    Expert Opin Biol Ther; 2001 May; 1(3):401-12. PubMed ID: 11727514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization strategy for prevention of congenital cytomegalovirus infection.
    Pass RF
    Infect Agents Dis; 1996 Oct; 5(4):240-4. PubMed ID: 8884369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus vaccine: persistence of humoral immunity following immunization of renal transplant candidates.
    Sachs GW; Simmons RL; Balfour HH
    Vaccine; 1984 Sep; 2(3):215-8. PubMed ID: 6099649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccines for the prevention of human cytomegalovirus infection.
    Plotkin SA; Starr SE; Friedman HM; Gonczol E; Brayman K
    Rev Infect Dis; 1990; 12 Suppl 7():S827-38. PubMed ID: 2173112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.